新型镇静药物瑞马唑仑临床应用研究进展  

Research progress of clinical application of new sedative Remimazolam

作　　者：陈康康 张志宇 张艺佳 梁映霞[1] CHEN Kangkang;ZHANG Zhiyu;ZHANG Yijia;LIANG Yingxia(College of Anesthesiology,Weifang Medical College,Weifang 261053,China)

机构地区：[1]潍坊医学院麻醉学院,山东潍坊261053 [2]潍坊医学院附属医院创伤外科,山东潍坊261035

出　　处：《陕西医学杂志》2023年第8期1106-1109,共4页Shaanxi Medical Journal

基　　金：国家自然科学基金资助项目(81300969);山东省自然科学基金资助项目(ZR2020MH130);山东省医药卫生科研项目(202004070430)。

摘　　要：新型镇静药物甲苯磺酸瑞马唑仑(简称瑞马唑仑)作为一种超短效苯二氮[艹卓]类药物,具备起效快和恢复快,呼吸抑制轻、血流动力学稳定、长时间输注无蓄积、可被拮抗剂氟马西尼快速逆转、不依赖肝肾代谢、代谢物无药理活性等优点,已逐渐成为用于各种临床实践的潜在镇静药物。现就瑞马唑仑的药理学特性及其在无痛内镜检查、围术期全身麻醉、重症监护病房(ICU)镇静、不良反应等临床应用问题作一综述,为其临床安全用药提供参考。The new sedative remimazolam besylate(remimazolam),as an ultra-short-acting benzodiazepine,has the advantages of quick onset and fast recovery,mild respiratory depression,stable hemodynamics,no accumulation after long-term infusion,rapid reversal by antagonist flumazenil,independent of liver and kidney metabolism,and no pharmacological activity of metabolites.It has gradually become a potential sedative for various clinical practices.This article reviews the pharmacological characteristics of remimazolam and its clinical application in painless endoscopy,general anesthesia during the perioperative period,sedation in ICU,adverse reactions,in order to provide reference for its clinical safety.

关 键 词：瑞马唑仑 麻醉 镇静药 重症监护 苯二氮[艹卓]类 药理学 

分 类 号：R169.42[医药卫生—公共卫生与预防医学]